Recalls, market withdrawals, & safety alerts > bristol-myers squibb initiates a nationwide voluntary recall of coumadin (r) 1 mg tablet blister packs
Home 1 > Safety 2 > Recalls, Market Withdrawals, & Safety Alerts 3
Recall -- Firm Press Release
FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a
service to consumers, the media, and other interested parties. FDA does not endorse either the product or the
Bristol-Myers Squibb Initiates a Nationwide Voluntary Recall of Coumadin® 1 mg Tablet Blister
-Recall Involves 1 mg Physician Sample Blister Packs and 1 mg Hospital Blister Packs Only-
FOR IMMEDIATE RELEASE
-- July 12, 2010 - Bristol-Myers Squibb initiates a voluntary recall of 3 lots of
physician sample blister packs of Coumadin® 1 mg tablets and 5 lots, of Coumadin 1 mg tablet hospital unit
dose (HUD) blister packs. The following lot numbers are included in this recall: Physician Sample Blister Packs:
Lot# 9A48931A, 9A48931B, 9A48931C, expiration January 2012; HUD Blister Pack: Lot# 8F34006B, 8K44272A,
8K46168A, 9F44437A and 9K58012B with expiry dates between June 2011 and November 2012. The recall is a
precautionary measure based upon the company’s determination that some of the tablets, over time, may not
meet specification for isopropanol. Isopropanol is used to maintain the active ingredient, Coumadin, in the
crystalline state, and could affect the therapeutic levels of the active ingredient.
Coumadin is prescribed to treat or prevent blood clots. A decrease of active ingredient may increase the risk of
clots which could lead to heart attack or stroke and if there is too much active ingredient, there is an increased
risk of bleeding.
The recall only involves Coumadin 1 mg tablet blister-packs distributed in the U.S. This recall does not involve
Coumadin 1 mg supplied in bottles or any other strengths and dosage forms of the product. Patients who may
have product from the subject lots should contact their physicians to ensure that their anticoagulation therapy is
To date, the company has not received any reports of adverse events related to this issue. Bristol-Myers Squibb
is committed to ensuring patient safety and is working to resolve this issue quickly and appropriately. The
company has notified the U.S. Food and Drug Administration (FDA), and has issued recall communications to allphysicians 9 and other customers 10 involved.
Any adverse reactions may also be reported to the FDA's MedWatch Program by fax at 1-800-FDA-0178, by mail
at MedWatch, HF-2, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website atwww.fda.gov 11.
Healthcare professionals and customers may call the following for assistance if they have further questions
RSS Feed for FDA Recalls Information 12 [what's this? 13]
Links on this page:
JOBNAME: cno 25#1 2005 PAGE: 1 OUTPUT: Fri February 11 20:34:45 2005lww/cno/94412/WNO160361Prod #: WNO160361Howard D. Pomeranz, MD, PhD and Abdhish R. Bhavsar, MDAbstract: Seven patients, aged between 50 and 69 years,had typical features of nonarteritic anterior ischemic opticThe medical records of seven patients in whomneuropathy (NAION) within 36 hours after ingestion ofNAION developed sub
PF-O3 & PF-04 Print Head Warranty Terms & Conditions The Canon companies listed beneath these warranty terms warrant the print head of the PF- O3 and PF-04 series (“Print Head”) sold in the EEA and Switzerland to be in good working order under normal use and service during the warranty period. In the event that a Print Head is found to be defective within the warranty period,